TransMedics Group (TMDX) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

TransMedics Group (TMDX) overview

TransMedics Group (TMDX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 605m and operating profit of USD 109m; the year-end share price was 121.65 USD and market capitalisation was USD 4,169m. TransMedics Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get TransMedics Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 473mFY 2025
Share price121.65 USDFY 2025 year end
RevenueUSD 605mFY 2025
Operating profitUSD 109mFY 2025
Net earningsUSD 190mFY 2025
Market capitalisationUSD 4,169mFY 2025 year end

About TransMedics Group

TransMedics develops organ preservation technology and transplant logistics services for transplant programs. Its Organ Care System products perfuse, monitor, and support donor hearts, lungs, and livers outside the body, with products for each organ. The company also provides organ procurement, perfusion management, and transportation coordination through its National OCS Program, using clinical specialists, procurement surgeons, and air and ground transport.

Generate the TransMedics Group report

TransMedics Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for TransMedics Group and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on TransMedics Group

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.